Tilray Brands Joins Frankfurt Stock Exchange, Boosting European Investor Access
Tilray Brands joins Frankfurt Stock Exchange, boosting European liquidity and investor reach for the cannabis & hemp leader.
2 minutes to read
TILRAY BRANDS INC
Tilray Brands Expands Medical Cannabis Access for UK Veterans with Lyphe Clinic
Tilray Brands expands medical cannabis for UK veterans, launching a dedicated Lyphe clinic program amid DEA scrutiny—evidence‑based relief for veterans.
3 minutes to read
Tilray Brands Q3 Break‑Even: Record Revenue, Narrow Loss, Yet Market Skepticism Persists
Tilray Brands Q3 tops expectations with record revenue, a narrowed loss, and a positive EPS, yet market sentiment remains cautious amid high valuation and ongoing net‑loss pressure.
4 minutes to read
Tilray Brands Faces Wall‑Street Skepticism Amid Australian Expansion and Uncertain Growth
Tilray Brands faces a pivotal pivot: Wall Street shifts from “Sell” to “Hold” as the company expands into Australia and partners with Cheba Hut, yet its earnings lag, valuation strains, and volatile stock keep investors wary. Explore whether this me…
4 minutes to read
Tilray Brands Expands in Australia, Boosts Global Reach Amid Stock Volatility
Tilray Brands expands its medical cannabis portfolio in Australia, partners with Breckenridge Distillery for U.S. growth, yet faces stock volatility amid market uncertainty.
3 minutes to read
Tilray Surges as U.S. Cannabis Rescheduled to Schedule III: Investors Rush to Medical Market
Tilray Brands surges as cannabis moves to Schedule III, launching Tilray Medical USA to tap a growing U.S. medical market—investors eye a new growth wave.
4 minutes to read
Tilray Brands Hits Record Q1 Revenue, Returns to Profitability in Fiscal 2026
Tilray Brands Inc. reported a record $210 million in Q1 fiscal 2026 revenue and turned a profit of $1.5 million, marking a significant turnaround for the company.
2 minutes to read